Management of Type 2 Diabetes: 2021 ADA Recommendations

[Pages:86]Management of Type 2 Diabetes: 2021 ADA Recommendations

Natalie Levy, MD Associate Professor, NYU School of Medicine Director, Bellevue Primary Care Diabetes Program

2_5_21

Type 2 Diabetes: ADA management recommendations

? Blood Glucose ? Blood Pressure ? LDL ? If time allows

? Pre Diabetes ? DM Outreach in the Time of Covid

Blood Glucose

? Blood Glucose-lowering Medication Framework: ADA 2021 ? Review GLP1-RA ? Review SGLT2i ? Operationalize This ? Pop-Quiz Questions

GLP1-RA

? Glucagon-like Peptide 1 Receptor Agonist ? GLP1: Secreted by the L cells in the small intestine

? Increase Insulin ? Decrease Glucagon ? Slow gastric emptying ? Increase satiety ? Improved Blood Glucose Control

Patients

MACE Hazard ratio

Liraglutide Leader 2016

81% ASCVD

0.87 (0.78-0.97)

HHF Hazard Ratio

Macro-albuminuria Hazard Ratio

0.87 (0.73-1.05)

0.74 (0.60-0.91)

SQ Semaglutide Sustain 2016

72% ASCVD

0.74 (0.58-0.95)

Dulaglutide Rewind 2019

31% ASCVD

0.88 (0.79-0.99)

1.11 (.77-1.61)

0.54 (0.37-0.57)

0.93 (0.77-1.12)

0.77 (0.68-0.87)

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download